Previous close | 0.0395 |
Open | 0.0390 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0375 - 0.0400 |
52-week range | 0.0300 - 0.1000 |
Volume | |
Avg. volume | 875,844 |
Market cap | 39.462M |
Beta (5Y monthly) | 0.25 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0090 |
Earnings date | 14 Mar 2023 - 20 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk™ strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the la
ANN ARBOR, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Adviso
ANN ARBOR, Mich., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has nearly closed out its $8 million in convertible debenture with Yorkville Advisors. Over the last 23 months, the Company has converted more than 98% of this debt to equity. Kraig Labs remains in one of the strongest financial positions in the Company's hi